Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24198129 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EGAAHPGDTSHR | |
| SCHEMBL2937272 | 0.78 | CA12 (0.47) | CNR2NR4A2ALDH1A1KDM4EGAA | |
| SCHEMBL69393 | 0.78 | NR4A2 (0.44) | CNR2NR4A2CHEK1ALDH1A1KDM4E | |
| SCHEMBL256714 | 0.78 | CNR2 (0.44) | CNR2NR4A2ALDH1A1KDM4EGAA | |
| SCHEMBL28043504 | 0.76 | KDM4E (0.42) | ALDH1A1KDM4EHPGDLMNASMN1; SMN2 | |
| SCHEMBL13729391 | 0.76 | CNR2 (0.43) | CNR2NR4A2CHEK1ALDH1A1KDM4E | |
| SCHEMBL21366811 | 0.76 | CNR2 (0.43) | CNR2NR4A2CHEK1ALDH1A1KDM4E | |
| SCHEMBL24840712 | 0.76 | CNR2 (0.43) | CNR2NR4A2ALDH1A1KDM4EGAA | |
| SCHEMBL30478971 | 0.76 | CNR2 (0.43) | CNR2NR4A2ALDH1A1KDM4EGAA | |
| SCHEMBL27969448 | 0.76 | ALDH1A1 (0.46) | CNR2ALDH1A1KDM4EGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170921-A | Synthetic method of 3-chloropyrrole-2-methyl formate | 上海博黑生物科技有限公司 | 2020-05-19 | — | — | CN | claimed |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| EP-4652164-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651944-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025235872-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4638446-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | KHORA SPV 1, LLC | 2025-05-22 | — | — | US | disclosed |
| CN-119371425-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010089084-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2010-08-12 | — | — | WO | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009117157-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1519729-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003099286-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624043-B2 | Compositions useful for treating disorders related to kit | KIT, RET, SLC26A4 | CNR2 4478/4885NR4A2 3372/4885CHEK1 1102/4885 |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | CNR2 3261/4885NR4A2 669/4885CHEK1 328/4885 |
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | CNR2 68/4885NR4A2 1084/4885CHEK1 2005/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | CNR2 4115/4885NR4A2 2805/4885CHEK1 2588/4885 |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | CDK4, CDK6, CDK2 | CNR2 4430/4885NR4A2 1469/4885CHEK1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.